Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019704 | 0.93 | KDM4E (0.41) | TSHRALDH1A1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL1018936 | 0.89 | HTT (0.47) | HTTSMN1; SMN2MEN1MAPK1KMT2A | |
| SCHEMBL1019280 | 0.86 | MEN1 (0.45) | TSHRALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL1020048 | 0.86 | MEN1 (0.42) | TSHRALDH1A1KDM4ESMN1; SMN2CYP2D6 | |
| SCHEMBL1019822 | 0.85 | KDM4E (0.40) | TSHRALDH1A1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL1018530 | 0.85 | TP53 (0.42) | TSHRHTTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL1019060 | 0.84 | DRD4 (0.45) | ALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL1019900 | 0.83 | ALDH1A1 (0.42) | TSHRALDH1A1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL1021466 | 0.83 | HTT (0.47) | HTTSMN1; SMN2MEN1MAPK1KMT2A | |
| SCHEMBL1019245 | 0.82 | KDM4E (0.45) | TSHRALDH1A1KDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | claimed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | claimed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | claimed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | claimed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | claimed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | TSHR 4169/4885ALDH1A1 1749/4885KDM4E 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.